{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:28:29Z","timestamp":1791170909281,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":4147,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Association pour la Recherche contre le Cancer","award":["3229"],"award-info":[{"award-number":["3229"]}]},{"name":"Fondation Langlois"},{"DOI":"10.13039\/501100009895","name":"Canc\u00e9rop\u00f4le Grand Ouest","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009895","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1093\/annonc\/mdn163","type":"journal-article","created":{"date-parts":[[2008,4,13]],"date-time":"2008-04-13T00:14:12Z","timestamp":1208045652000},"page":"1485-1487","source":"Crossref","is-referenced-by-count":18,"title":["Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1\/NA2 polymorphism does not influence response and survival after rituximab treatment"],"prefix":"10.1016","volume":"19","author":[{"given":"G.","family":"Cartron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ohresser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Solal-C\u00e9ligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Colombat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Watier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdn163_bb0010","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn163_bb0015","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene","volume":"98","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn163_bb0020","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphism independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdn163_bb0025","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn163_bb0030","first-page":"5866","article-title":"Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined innumodeficiency mouse model","volume":"9","author":"Hernandez-Ilizalturri","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdn163_bb0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.immuni.2005.05.010","article-title":"FcgammaRIV: a novel FcR with distinct IgG subclass specificity","volume":"23","author":"Nimmerjahn","year":"2005","journal-title":"Immunity"},{"key":"10.1093\/annonc\/mdn163_bb0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s002770050396","article-title":"The IgG Fc receptor family","volume":"76","author":"Gessner","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdn163_bb0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.170.2.481","article-title":"Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions","volume":"170","author":"Ravetch","year":"1989","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdn163_bb0050","first-page":"624","article-title":"Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes","volume":"83","author":"Bredius","year":"1994","journal-title":"Immunology"},{"key":"10.1093\/annonc\/mdn163_bb0055","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI114566","article-title":"Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities","volume":"85","author":"Salmon","year":"1990","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdn163_bb0060","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s002770050396","article-title":"The IgG Fc receptor family","volume":"76","author":"Gessner","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdn163_bb0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn163_bb0070","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1537-2995.1995.35195090663.x","article-title":"NA gene frequencies in the German population, determined by polymerase chain reaction with sequence-specific primers","volume":"35","author":"Bux","year":"1995","journal-title":"Transfusion"},{"key":"10.1093\/annonc\/mdn163_bb0075","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/oxfordjournals.jhered.a111573","article-title":"Genopop (version 1.2) a population genetics software for exact test and ecumenicism","volume":"86","author":"Raymond","year":"1995","journal-title":"J Heredity"},{"key":"10.1093\/annonc\/mdn163_bb0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00251-003-0574-9","article-title":"Evidence for non-random distribution of Fcgamma receptor genotype combinations","volume":"55","author":"van der Pol","year":"2003","journal-title":"Immunogenetics"},{"key":"10.1093\/annonc\/mdn163_bb0085","doi-asserted-by":"crossref","first-page":"486a","DOI":"10.1182\/blood.V108.11.486.486","article-title":"Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up of 7 years","volume":"108","author":"Colombat","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn163_bb0090","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1182\/blood-2005-02-0798","article-title":"Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies","volume":"106","author":"Ternant","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdn163_bb0095","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1080\/17402520500182329","article-title":"Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a sever combined immunodeficiency mouse lymphoma model","volume":"46","author":"Hernandez-Ilizalturri","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdn163_bb0100","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2402995","article-title":"Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy","volume":"17","author":"van der Kolk","year":"2003","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdn163_bb0105","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.critrevonc.2006.11.010","article-title":"Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment","volume":"62","author":"Loisel","year":"2007","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419402585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419402585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/8\/1485\/627397\/mdn163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:41:27Z","timestamp":1624437687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419402585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0923753419402585"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdn163","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}